Patents Assigned to Survac APS
  • Survivin-derived peptides and uses thereof
    Patent number: 9534030
    Abstract: MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-?-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses thereof.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: January 3, 2017
    Assignee: SURVAC APS
    Inventors: Eivind Per Thor Straten, Mads Hald Andersen
  • SURVIVIN-DERIVED PEPTIDES AND USES THEREOF
    Publication number: 20130115216
    Abstract: MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-?-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses thereof.
    Type: Application
    Filed: September 28, 2012
    Publication date: May 9, 2013
    Applicant: SURVAC APS
    Inventor: SURVAC APS
  • Survivin-derived peptides and use thereof
    Patent number: 8318174
    Abstract: MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-?-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses thereof.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: November 27, 2012
    Assignee: Survac APS
    Inventors: Evind Per Thor Straten, Mads Hald Andersen
  • SURVIVIN PEPTIDE VACCINE
    Publication number: 20110091489
    Abstract: The present invention relates to a therapeutic vaccine comprising one or more survivin polypeptide fragments. The vaccine can be used for prophylactic, ameliorating and/or curative treatment of e.g. cancer diseases. The invention further relates to methods of combination treatment.
    Type: Application
    Filed: February 3, 2006
    Publication date: April 21, 2011
    Applicant: Survac ApS
    Inventor: Mads Hald Andersen
  • Survivin-derived peptides and use thereof
    Patent number: 7892559
    Abstract: MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-?-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses hereof.
    Type: Grant
    Filed: November 19, 2003
    Date of Patent: February 22, 2011
    Assignee: Survac APS
    Inventors: Eivind Per Thor Straten, Mads Hald Andersen
  • Proteins belonging to the Bcl-2 family and fragments thereof, and their use in cancer patients
    Patent number: 7842294
    Abstract: The present invention relates to proteins belonging to the Bcl-2 family and peptides fragments thereof for use in pharmaceutical compositions. The disclosed proteins and peptide fragments are in particularly useful in vaccine compositions for treatment of cancer. The invention furthermore relates to methods of treatment using said compositions. It is also an aspect of the invention to provide T-cells and T-cell receptors specifically recognising the disclosed proteins and peptide fragments.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: November 30, 2010
    Assignee: Survac APS
    Inventors: Mads Hald Andersen, Per Thor Straten
  • Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
    Publication number: 20080050396
    Abstract: The present invention relates to proteins belonging to the Bcl-2 family and peptides fragments thereof for use in pharmaceutical compositions. The disclosed proteins and peptide fragments are in particularly useful in vaccine compositions for treatment of cancer. The invention furthermore relates to methods of treatment using said compositions. It is also an aspect of the invention to provide T-cells and T-cell receptors specifically recognising the disclosed proteins and peptide fragments.
    Type: Application
    Filed: November 18, 2004
    Publication date: February 28, 2008
    Applicant: Survac ApS
    Inventors: Mads Hald Andersen, Per Thor Straten
  • Survivin-derived peptides and uses thereof
    Patent number: RE48522
    Abstract: MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-?-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses thereof.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: April 20, 2021
    Assignee: SURVAC APS
    Inventors: Eivind Per Thor Straten, Mads Hald Andersen